JMP Securities Reiterates Market Outperform on Sagimet Biosciences, Maintains $31 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has reiterated a 'Market Outperform' rating on Sagimet Biosciences (NASDAQ:SGMT), maintaining a price target of $31.
December 05, 2023 | 2:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities analyst Jonathan Wolleben reaffirmed a 'Market Outperform' rating on Sagimet Biosciences, with a price target of $31, indicating a positive outlook for the stock.
The reiteration of a 'Market Outperform' rating and the maintenance of a $31 price target by a reputable analyst like Jonathan Wolleben could lead to increased investor confidence in SGMT, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100